Home Newsfeeds Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023

byBenzinga Newsdesk

January 25, 2023

1 minute read

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy

Bolsters Presence in Neuroscience

Expected to be Accretive in 2023

M&A
News

Pursuant To Merger Agreement Terms, Concentra Merger Sub II And Theseus Determine Additional Price Per Share Max Of $0.15/Share; Cash Amount Paid In Offer Is $4.05/Share

By Benzinga Newsdesk

January 30, 9:29 AM

As previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered into a merger agreement (the "Merger Agreement")

THRX

Reported Late Thursday Feb 23, Hewlett Packard Enterprise Announces Acquisition Of Athonet, Doubling Down On Private 5G And Extending Leadership In Wireless Connectivity; No Financial Terms Disclosed

By Happy Mohamed

February 24, 1:29 AM

Athonet acquisition strengthens HPE's private networking capabilities to help enterprise customers accelerate 5G deployments and telco customers drive new revenue streams Hewlett Packard

HPE

U.S. Imposes Sanctions On Russians Under Provisions Targeting Human Rights Abuse And Corruption

By Benzinga Newsdesk

March 3, 11:23 AM

-Treasury Website

SPY

5 Things To Know In Investing This Week: The Let’s Look At The Data Issue

By Gary Brode

May 22, 1:35 PM

DKI stock pick, AuthID, announces 1Q revenue almost as high as all of 2023. Guidance indicates they expect quarterly revenue to double this year. They still need to announce new contracts, but the year is off to an excellent start. Lyn Alden @LynAldenContact makes a brilliant point explaining fiscal dominance.

AUID

Catalyst Pharmaceuticals Completes The Acquisition Of U.S. Rights To FYCOMPA (Perampanel) CIII

Related Posts

Pursuant To Merger Agreement Terms, Concentra Merger Sub II And Theseus Determine Additional Price Per Share Max Of $0.15/Share; Cash Amount Paid In Offer Is $4.05/Share

Reported Late Thursday Feb 23, Hewlett Packard Enterprise Announces Acquisition Of Athonet, Doubling Down On Private 5G And Extending Leadership In Wireless Connectivity; No Financial Terms Disclosed

U.S. Imposes Sanctions On Russians Under Provisions Targeting Human Rights Abuse And Corruption

5 Things To Know In Investing This Week: The Let’s Look At The Data Issue